Amundi Russell 2000 UCITS ETF USD Acc

RAPPORT

publicitaire mededelingen

31/08/2026

AANDEEL

Error during the generation of the module

Error during the generation of the module

Error during the generation of the module

Error during the generation of the module

Notation Morningstar

Morningstar-beoordeling © : **3 sterren**
Morningstar-categorie © :
EAA FUND US SMALL-CAP EQUITY
Beoordelingsdatum : **31/07/2026**
Aantal fondsen in de categorie : **385**

Error during the generation of the module

Error during the generation of the module

Error during the generation of the module

Error during the generation of the module

Risico-indicator ***(Bron: Fund Admin)***

⚠ Voor de risico-indicator wordt ervan uitgegaan dat u het product houdt gedurende 5 jaar.
De samenvattende risico-indicator is een richtsnoer voor het risiconiveau van dit product ten opzichte van andere producten. De indicator laat zien hoe groot de kans is dat beleggers verliezen op het product wegens marktontwikkelingen of doordat er geen geld voor betaling is.

Error during the generation of the module

Error during the generation of the module

Error during the generation of the module

Error during the generation of the module

Error during the generation of the module

Ontmoet het team

Sébastien Foy

Responsable de l'équipe de gestion - Indiciel Synthétique



Hamid Drali

Zaakvoerder van portefeuille

Moussa Thioye

Co-Belangrijkste beheerder

Gegevens van de index (bron : Amundi)

Beschrijving

De Russell 2000 Index is een aandelenindex die representatief is voor 2000 op de Amerikaanse markt verhandelde smallcapeffecten.

Kenmerken (bron : Amundi)

Klasse van Activa : **Aandeel**
Exposure : **VS**
Referentie valuta : **USD**

Aantal effecten : **1953**

Voornaamste lijnen van de index (bron : Amundi)

	% van vermogen (index)
JFROG LTD	0.34%
MOOG INC-CL A	0.34%
UMB FINANCIAL CORP	0.34%
GLAUKOS CORP	0.33%
BRINKER INTERNATIONAL INC	0.32%
BRIGHTSPRING HEALTH SERVICES	0.31%
CYTOKINETICS INC	0.30%
TWIST BIOSCIENCE CORP	0.29%
KRYSTAL BIOTECH INC	0.29%
OLD NATIONAL BANCORP	0.29%
Totaal	**3.16%**

Alleen ter illustratie en geen aanbeveling om effecten te kopen of verkopen.

Geografische spreiding (Bron: Amundi)



Sectorspreiding (bron : Amundi)



AANDEEL

Koersgegevens van de ETF (bron : Amundi)

Genoteerd	Valuta	Ticker Bloomberg	INAV Bloomberg	RIC Reuters	INAV Reuters
Six Swiss Exchange	USD	RS2U SW	IRS2U	RS2U.S	IRS2U=BNPP
Euronext Paris	USD	RS2U FP	IRS2U	RS2U.PA	IRS2U=BNPP
LSE	GBP	RS2G LN	-	RS2G.L	-
LSE	USD	RS2U LN	IRS2U	RS2U.L	IRS2U=BNPP

Contactpersonen

Contactpersonen ETF verkoop

Frankrijk & Luxemburg	+33 (0)1 76 32 65 76
Duitsland & Oostenrijk	+49 (0) 800 111 1928
Italië	+39 02 0065 2965
Zwitserland (Duits)	+41 44 588 99 36
Zwitserland (Frans)	+41 22 316 01 51
Verenigd Koninkrijk (particuliere markt)	+44 (0) 20 7 074 9598
Verenigd Koninkrijk (institutionele markt)	+44 (0) 800 260 5644
Nederland	+31 20 794 04 79
Skandinavische landen	+46 8 5348 2271
Hong Kong	+65 64 39 93 50
Spanje	+34 914 36 72 45

Contactpersonen ETF Capital Market

Téléphone	+33 (0)1 76 32 19 93
Bloomberg IB Chat	Capital Markets Amundi ETF
	Capital Markets Amundi HK ETF

Contactpersonen ETF Makelaars

BNP Paribas	+33 (0)1 40 14 60 01
Kepler Cheuvreux	+33 (0)1 53 65 35 25

Amundi Contactpersonen

Amundi ETF
90 bd Pasteur
CS 21564
75 730 Paris Cedex 15 - France
Hotline : +33 (0)1 76 32 47 74
info-etf@amundi.com

Leveranciers van Index

AANDEEL ■

Belangrijke informatie

Note on the Fund management company and the fund
Sub-fund of the Luxembourg SICAV Amundi Index Solutions (the 'Sub-fund' or the 'Fund' and the 'SICAV'). The SICAV is an undertaking for collective investment in transferable securities existing under Part I of the Luxembourg law of 17 December 2010, organised as a société dinvestissement à capital variable and registered with the Luxembourg Trade and Companies Register under number B206810. The SICAV has its registered office at 5, allée Scheffer, L-2520 Luxembourg. The Sub-fund has been authorised for public sale by the Commission de Surveillance du Secteur Financier of Luxembourg and in France by the AMF. The SICAV has other Sub-funds which are described in the prospectus. Not all sub-funds will necessarily be registered or authorized for sale in jurisdictions of all investors.

The Fund is described in a Key Information Document (KID), or Key Investor Information Document (KIID) for UK investors, and prospectus. The Funds KID, or KIID for UK investors, must be made available to potential subscribers prior to subscription.
The Funds reference material (KIID, prospectus, annual and semi-annual reports) can be obtained from Amundi on request, or obtained via the amundietf.com website.
In the United Kingdom (the “UK”), this website is being issued by Amundi (UK) Limited, 77 Coleman Street, London EC2R 5BJ, UK. Amundi (UK) Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) and entered on the FCA’s Financial Services Register under number 114503. This may be checked at https://register.fca.org.uk/ and further information of its authorisation is available on request. Each fund and its relevant sub-fund(s) under its respective fund range that is referred to in this website (each, a “Fund”) is a recognised collective investment scheme for the purposes of Section 264 of the Financial Services and Markets Act 2000 (the “FSMA”). Potential investors in the UK should be aware that none of the protections afforded by the UK regulatory system will apply to an investment in a Fund and that compensation will not be available under the UK Financial Services Compensation Scheme.
Regarding Funds admitted on a regulated market, the listing is subject to a volatility control mechanisms to ensure that the ETF price does not deviate significantly from a reference price set by the listing rules of the relevant regulated market, notably through the implementation of a trading halt mechanism in case of significant deviation from this reference price.

The Fund offers no capital guarantee. Investors may not get back the full amount of their initial investment, particularly in the event that the benchmark index falls. Subscribing to a UCITS may involve risks. Potential investors are advised to read the Funds risk profile, which is described in detail in the prospectus. The amount that is reasonable to invest in the Fund will depend on the personal circumstances of each investor. To determine this amount, investors should take into account their financial situation, personal assets, and current and future requirements, as well as considering their willingness to accept risks or conversely their preference to invest cautiously. Investors are also strongly recommended to sufficiently diversify their investments so as to avoid being exposed solely to the risks of this Fund. Investors should therefore seek advice in this regard from their usual advisors (legal, tax, financial and/or accounting) before purchasing any units of the Fund.
The source of the data contained in this document is Amundi Asset Management unless otherwise stated.

Policy regarding portfolio transparency and warning on secondary market
The policy regarding portfolio transparency and information on the funds assets are available on amundietf.com. Shares purchased on the secondary market cannot usually be sold directly back to the fund. Investors must buy and sell shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. Investors may pay more than the current net asset value when buying shares and may receive less than the current net asset value when selling them.

« Technische ‘net asset values (netto vermogens waarden)’ kunnen worden berekend en gepubliceerd voor elke kalenderdag (behalve voor zaterdag en zondag) als deze dag noch een werkdag noch een transactiedag is. Deze technische ‘net asset values’ zijn louter indicatief en vormen geen basis voor het kopen, omwisselen, verzilveren en/of overdragen van aandelen. ”